No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 8 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Bon Natural Life Limited (BON) stock was $1.17 as of Oct 5, 2026, 4:00 PM EDT, up 2.74% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -41.4% · 3-year avg -77.5%/yr · 5-year avg -77.0%/yr
Bon Natural Life Limited, accompanied by its various subsidiaries, focuses on the innovation, production, and worldwide distribution of active functional compounds sourced from natural plant extracts. Its operations span the People's Republic of China and international markets.
Chemicals - Specialty · Xi'an, SA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2024-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Dec 2, 2026
57 days away
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$8.10M
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BON | $7.13M | $1.17 | +2.74% | -41.35% | -77.03% | N/A | N/A |
| 2ATCX | $7.64M | $2.75 | -5.50% | -91.60% | -23.77% | N/A | vs BON |
| 3BGL | $8.31M | $0.19 | +0.95% | -97.96% | N/A | N/A | vs BON |
| 4CHNR | $4.86M | $3.87 | +0.26% | -21.41% | -39.47% | -25.01% | vs BON |
| 5AEHL | $10.59M | $10.86 | +8.60% | -96.58% | -83.99% | -64.42% | vs BON |
| 6CAPS | $2.17M | $0.14 | -1.72% | -88.97% | -58.05% | -41.42% | vs BON |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.17
High
N/A
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $90.71M | $90.71M | $90.71M | 1 |
| FY 2027 | $104.90M | $104.90M | $104.90M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
